UroGen Pharma Ltd. (NASDAQ: URGN) reported that 72.2% of patients who achieved complete response maintained their response at 24 months ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE